Successful treatment of platelet transfusion refractoriness: The use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia

European Journal of Haematology

Volumn 60, Issue 2, 1998, Pages 112-118

  Kekomaki S ^a   Volin, L ^b   Koistinen, P ^c   Koivunen, E ^d   Koskimies, S ^a   Ruutu, T ^b   Timonen, T ^c   Kekomaki R ^a  

^a FINNISH RED CROSS BLOOD SERVICE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Alloimmunization; HPA; Platelet; Refractoriness; Transfusion

Indexed keywords

ALLOANTIBODY; ALLOANTIGEN; HLA ANTIGEN; THROMBOCYTE ANTIGEN;

ADULT; AGED; ALLOIMMUNIZATION; ARTICLE; BLOOD DONOR; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; FEMALE; HLA MATCHING; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION;

EID: 0031896107     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01007.x     Document Type: Article

References (34)

1. SIRCHIA G, PARRAVICINI A, REBULLA P, GREPPI N, SCALAMOGNA M, MORELATI F. Effectiveness of red blood cells filtered through cotton wool to prevent antileukocyte antibody production in multitransfused patients. Vox Sang 1982: 42: 190-197.
2. SCHIFFER CA, DUTCHER JP, AISNER J, HOGGE D, WIERNIK PH, REILLY JP. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983: 62: 815-820.
3. MURPHY MF, METCALF P, THOMAS H, et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 1986: 62: 529-534.
4. ANDREU G, DEWAILLY J, LEBERRE C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988: 72: 964-969.
5. OKSANEN K, KEKOMÄKI R, RUUTU T, KOSKIMIES S, MYLLYLÄ G. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components. A randomized trial. Transfusion 1991: 31: 588-594.
6. BRAND A, CLAAS FHJ, VOOGT PJ, WASSER MNJM, EERNISSE JG. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox Sang 1988: 54: 160-166.
7. BISHOP JF, MATTHEWS JP, YUEN K, MCGRATH K, WOLF MM, SZER J. The definition of refractoriness to platelet transfusions. Transfus Med 1992: 2: 35-41.
8. HEDDLE NM. The efficacy of leukodepletion to improve platelet transfusion response: a critical appraisal of clinical studies. Transfus Med Rev 1994: 8: 15-28.
9. SLICHTER SJ. Mechanisms and management of platelet refractoriness. In: NANCE SJ, ed. Transfusion Medicine in the 1990s. Arlington, VA: American Association of Blood Banks, 1990: 5-177.
10. DOUGHTY HA, MURPHY MF, METCALFE P, ROHATINER AZS, LISTER TA, WATERS AH. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994: 66: 200-205.
11. YANKEE RA, GRAFF KS, DOWLING R, HENDERSON ES. Selection of unrelated compatible platelet donors by lymphocyte HLA matching. N Engl J Med 1973: 288: 760-764.
12. MOROFF G, GARRATTY G, HEAL JM, et al. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 1992: 32: 633-640.
13. BRAND A, VAN LEEUWEN A, EERNISSE JG, VAN ROOD JJ. Platelet transfusion therapy. Optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests. Blood 1978: 51: 781-788.
14. YAM P, PETZ LD, SCOTT EP, SANTOS S. Platelet crossmatch tests using radiolabelled staphylococcal protein A or peroxidase anti-peroxidase in alloimmunized patients. Br J Haematol 1984: 57: 337-347.
15. WARE R, REISNFR EG, ROSSE WF. The use of radio-labeled and fluorescein-labeled antiglobulins in assays to predict platelet transfusion outcome. Blood 1984: 63: 1245-1248.
16. HEAL JM, BLUMBERG N, MASEL D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987: 70: 23-30.
17. BRUBAKER DB, DUKE JC, ROMINE M. Predictive value of enzyme-linked immunoassay platelet crossmatching for transfusion of platelet concentrates to alloimmunized recipients. Am J Hematol 1987: 24: 375-387.
18. MILLARD FE, TANI P, MCMILLAN R. A specific assay for HLA antibodies: applications to platelet donor selection. Blood 1987: 70: 1495-1499.
19. VON DEM BORNE AEGK, OUWEHAND W, KUIJPERS RWAM. Theoretic and practical aspects of platelet crossmatching. Transfus Med Rev 1990: 4: 265-278.
20. WATERS AH, MINCHINTON RM, BELL R, FORD JM, LISTER TA. A cross-matching procedure for the selection of platelet donors for alloimmunized patients. Br J Haematol 1981: 48: 59-68.
21. KICKLER TS, BRAINE HG, NESS PM. The predictive value of crossmatching platelet transfusion for alloimmunized patients. Transfusion 1985: 25: 385-389.
22. LOHRMANN HP, BULL MI, DECTER JA, YANKEE RA, GRAW RG. Platelet transfusions from HL-A compatible unrelated donors to alloimmunized patients. Ann Int Med 1974: 80: 9-14.
23. DUQUESNOY RJ, FILIP DJ, RODEY GE, RIMM AA, ASTER RH. Successful transfusion of platelets 'mismatched' for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977: 2: 219-226.
24. NOVOTNY VMJ, VAN DOORN R, WITVLIET MD, CLAAS FHJ, BRAND A. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood 1995: 85: 1736-1741.
25. A2 using platelet protein blots. 10th Congress, International Society for Blood Transfusion and British Blood Transfusion Society, London, 1988: 131a.
26. A2) and multiple HLA antibodies. Transfusion 1988: 28: 597-600.
27. KICKLER T, KENNEDY SD, BRAINE HG. Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion 1990: 30: 622-625.
28. SCHNAIDT M, NORTHOFF H, WERNET D. Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients. Transfus Med 1996: 6: 111-114.
29. SZYMANSKI I, SAHLSTEDT L, RUUTU T, JÄRVENTIE G, KEKOMÄKI R. Persistence of an antibody to the human platelet antigen, HPA-Sb (Br(a)) after successful bone marrow transplantation (BMT). Blood 1992: 80(suppl 1): 217a.
30. KEKOMÄKI S, PARTANEN J, KEKOMÄKI R. Platelet allo-antigens HPA-1, -2, -3, -5 and -6b in Finns. Transfus Med 1995: 5: 193-198.
31. KIEFEL V, SANTOSO S, WEISHEIT M, MUELLER-ECKHARDT C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for identification of platelet reactive antibodies. Blood 1987: 70: 1722-1726.
32. OKSANEN K, EBELING F, KEKOMÄKI R, et al. Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat. Vox Sang 1994: 67: 356-361.
33. a, involved in platelet transfusion refractoriness in a Japanese man. Vox Sang 1989: 56: 283-287.
34. OKSANEN K, ELONEN E. Impact of leucocyte-depleted blood components on the haematological recovery and prognosis of patients with acute myeloid leukaemia. Br J Haematol 1993: 84: 639-647.